Long Term Study of 650,000 Adults Links Common Irritable Bowel Syndrome Medications to Increased Mortality Risk

A 20-year study of 650,000 patients links antidepressants and antidiarrheals to a higher death risk in IBS care. Explore the long-term safety findings now.

By: AXL Media

Published: Apr 16, 2026, 11:06 AM EDT

Source: Information for this report was sourced from Cedars-Sinai Medical Center

Investigating the Longitudinal Safety of Digestive Health Therapies

A landmark real world study has sparked a critical re-evaluation of the pharmaceutical management of irritable bowel syndrome. Researchers at Cedars-Sinai Health Sciences University conducted an extensive analysis of electronic health records spanning nearly two decades to assess the long term safety profiles of common IBS drugs. With the condition affecting approximately 10% of the United States population, many patients begin treatment at a young age and remain on medications for several decades. Senior author Ali Rezaie noted that while standard clinical trials typically conclude in less than a year, this 20 year data set provides the first comprehensive look at the cumulative impact of these therapies on patient longevity.

Quantifying the Risks of Antidepressants and Antidiarrheals

The study analyzed data from more than 650,000 Americans and uncovered significant statistical associations between specific drug classes and mortality. According to the research published in Communications Medicine, the long term use of antidepressants was associated with a 35% increase in the risk of death. Furthermore, common opioid based antidiarrheal medications such as loperamide and diphenoxylate were linked to approximately twice the risk of death compared to patients who did not utilize these treatments. While antidepressants are not specifically approved by the FDA for IBS, they are frequently prescribed by clinicians to manage chronic pain and the sensory severity of the disorder.

Distinguishing Statistical Association from Direct Causality

It is critical to note that the research identifies a correlation rather than a direct causative link. The elevated mortality rates observed in the study may reflect a higher incidence of secondary health complications among long term medication users, including strokes, cardiovascular events, and physical falls. However, not all IBS treatments were associated with these risks. The analysis found that FDA approved IBS specific medications and antispasmodics did not show an increased risk of death, suggesting that certain classes of drugs may be inherently safer for chronic management. This distinction provides a roadmap for clinicians looking to optimize treatment plans while minimizing potential long term harm.